27.01.2025 07:30:00
|
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.
Since the last announcement of transactions under the program on January 20, 2025, the following transactions have been made:
Number of shares | Average purchase price, DKK | Transaction value, DKK | |
Accumulated until January 20, 2025 | 358,000 | 197.78 | 70,806,380 |
January 20, 2025 | 52,000 | 195.60 | 10,171,200 |
January 21, 2025 | 40,000 | 197.16 | 7,886,400 |
January 22, 2025 | 50,000 | 198.70 | 9,935,000 |
January 23, 2025 | 50,000 | 197.78 | 9,889,000 |
January 24, 2025 | 38,000 | 201.50 | 7,657,000 |
Accumulated under the program | 588,000 | 197.87 | 116,344,980 |
The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.
Following these transactions, Bavarian Nordic holds a total of 872,235 treasury shares, corresponding to 1.11 % of the Company’s share capital.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contact investors:
Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: + 45 53 88 06 03
Company Announcement no. 03 / 2025
Attachments
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bavarian Nordic A/Smehr Nachrichten
16.12.24 |
ROUNDUP/Wegen Mpox: Schule in NRW vorsorglich geschlossen (dpa-AFX) | |
11.12.24 |
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program (GlobeNewswire) | |
14.11.24 |
Ausblick: Bavarian Nordic stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
31.10.24 |
Erste Schätzungen: Bavarian Nordic vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
13.09.24 |
WHO segnet erstmals Mpox-Impfstoff ab (dpa-AFX) | |
29.08.24 |
MPox: Affenpocken-Impfstoff-Lieferungen von Bavarian Nordic in den Kongo verzögern sich (Spiegel Online) | |
26.08.24 |
Deutschland spendet Mpox-Impfstoff an betroffene Länder (dpa-AFX) | |
22.08.24 |
Bavarian Nordic: Das Unternehmen, das die Welt mit Mpox-Impfstoff versorgen soll (Spiegel Online) |
Analysen zu Bavarian Nordic A/Smehr Analysen
Aktien in diesem Artikel
Bavarian Nordic A/S | 25,53 | -4,20% |